🔍

MPSLTD - MPS

📊 NSE: MPSLTD 🏢 Computers - Software - Medium / Small 📅 Last Updated: 12/14/2025 10:02

📢 Recent Corporate Announcements

MPS Limited Acquires Unbound Medicine to Target $188B Healthcare AI Market

🟢 POSITIVE ⭐ 9/10

M&A 📅 25 Feb 2026, 08:33 PM

MPS Limited has detailed its acquisition of Unbound Medicine, Inc., a US-based leader in healthcare knowledge management, to pivot toward high-growth AI-driven intelligence. Unbound brings a robust subscription-based model with over 90,000 paid subscribers and 1,000+ healthcare facility clients. The acquisition targets a healthcare AI market projected to reach $188 billion by 2030, with a specific subsector CAGR of 42%. MPS plans to leverage its global infrastructure to expand Unbound's reach beyond North America into Europe and APAC, aiming for significant EBITDA uplift.

Unbound Medicine serves 1,000+ healthcare facilities and manages 5 million+ clinical lookups annually.
The business model is recurring revenue-based with low concentration risk; the largest customer contributes <$300,000.
Targets the AI-driven knowledge management market, expected to grow from $3 billion to $102 billion by 2034.
Acquisition includes a multidisciplinary team with an average tenure of 12 years and 20+ years of clinical expertise.
Strategic alignment with 'Vision 2027' to transition MPS from a content provider to a global intelligence powerhouse.

💡 Investors should look favorably on this acquisition as it shifts the company toward high-margin, recurring SaaS revenue in the resilient healthcare sector. Monitor the speed of global rollout and EBITDA margin improvements in subsequent quarters as integration synergies kick in.

MPS Limited Schedules Investor Call on Feb 18 for Unbound Medicine, Inc. Acquisition

🟡 NEUTRAL ⭐ 7/10

M&A 📅 17 Feb 2026, 04:00 PM

MPS Limited has announced an update to its conference call scheduled for February 18, 2026, at 7:00 P.M. IST regarding the acquisition of Unbound Medicine, Inc. The company has added a Zoom audio-video participation option to the existing dial-in facilities to facilitate better investor engagement. The acquisition is being conducted through its wholly-owned subsidiary, MPS North America LLC. Chairman and CEO Rahul Arora will lead the call to discuss the strategic implications of this US-based expansion.

Conference call scheduled for February 18, 2026, at 7:00 P.M. IST.
Discussion focused on the acquisition of Unbound Medicine, Inc., USA.
Deal executed via MPS North America LLC, a 100% wholly-owned subsidiary.
Management to provide details on the strategic rationale and financial impact of the US acquisition.

💡 Investors should attend the conference call to understand the valuation and synergy benefits of the Unbound Medicine acquisition. Monitor the impact of this acquisition on the company's North American revenue share and overall margins.

MPS Limited to Discuss Acquisition of Unbound Medicine Inc. in Upcoming Call

🟢 POSITIVE ⭐ 8/10

M&A 📅 10 Feb 2026, 02:11 AM

MPS Limited has scheduled a conference call for February 18, 2026, to provide details on the acquisition of Unbound Medicine, Inc., USA. The acquisition is being executed through its wholly-owned subsidiary, MPS North America LLC. Chairman and CEO Rahul Arora will lead the discussion to explain the strategic rationale and expected synergies. This move highlights the company's ongoing focus on inorganic growth and expansion within the North American market.

Conference call scheduled for Wednesday, February 18, 2026, at 07:00 P.M. IST.
Acquisition of US-based Unbound Medicine, Inc. by wholly-owned subsidiary MPS North America LLC.
Chairman and CEO Rahul Arora and senior management to address institutional investors and analysts.
Universal dial-in numbers for the event are +91 22 6280 1410 and +91 22 7115 8311.

💡 Investors should monitor the conference call for specific details regarding the acquisition cost, revenue multiples, and how this integration will impact the company's consolidated margins.

MPS Limited Completes Acquisition of Unbound Medicine, USA for USD 16.50 Million

🟢 POSITIVE ⭐ 9/10

M&A 📅 10 Feb 2026, 01:55 AM

MPS Limited, through its US subsidiary MPS North America LLC, has successfully completed the 100% acquisition of Unbound Medicine, Inc., USA. The transaction was finalized for a total consideration of USD 16.50 million following the satisfaction of customary closing conditions. As a result, Unbound Medicine has become a wholly-owned step-down subsidiary of MPS Limited effective February 9, 2026. This acquisition is part of the company's strategy to expand its footprint in the North American market and enhance its digital health and medical education offerings.

Acquisition of 100% stake in Unbound Medicine, Inc., USA successfully completed
Total transaction value fixed at USD 16.50 million subject to customary adjustments
Unbound Medicine is now a wholly-owned step-down subsidiary of MPS Limited
Completion follows the Stock Purchase Agreement originally signed on January 30, 2026
Funding arrangements for the acquisition were previously disclosed on February 4, 2026

💡 Investors should view this as a strategic growth move that strengthens MPS's international presence. Monitor upcoming quarterly results to assess the revenue contribution and margin impact of this new subsidiary.

MPS Limited Shareholders Approve Director Re-appointment and Office Relocation with 99%+ Majority

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 09 Feb 2026, 04:43 PM

MPS Limited has announced the successful passing of two special resolutions via postal ballot with overwhelming shareholder support. Mr. Suhas Khullar has been re-appointed as an Independent Director for a second five-year term, effective from January 1, 2026, to December 31, 2030. Additionally, shareholders approved the shifting of the company's registered office within Chennai to Gateway Office Parks, effective April 1, 2026. Both resolutions received over 99.9% approval from the voting shareholders, ensuring leadership continuity and administrative stability.

Re-appointment of Mr. Suhas Khullar as Independent Director approved for a 5-year term with 99.954% votes in favor
Shifting of Registered Office to Perungalathur, Chennai approved with 99.999% majority
Total of 1,29,87,750 votes were cast in favor of the director re-appointment resolution
The office relocation is scheduled to take effect from April 1, 2026, staying within the same ROC jurisdiction

💡 No action is required as these are routine governance and administrative matters. The high approval rates reflect strong shareholder alignment with the board's decisions.

MPS Limited Shareholders Approve Director Re-appointment and Office Relocation with 99.95% Majority

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 09 Feb 2026, 04:31 PM

MPS Limited has announced the successful passing of two special resolutions via postal ballot with overwhelming shareholder support. Mr. Suhas Khullar has been re-appointed as an Independent Non-Executive Director for a five-year term ending December 2030, receiving 99.95% of the votes. Additionally, shareholders approved the relocation of the company's registered office within Chennai to Gateway Office Parks, effective April 1, 2026. These approvals ensure management continuity and administrative transition for the upcoming fiscal years.

Re-appointment of Mr. Suhas Khullar as Independent Director approved for a 5-year term starting January 1, 2026.
The resolution for director re-appointment received 1,29,87,750 votes in favor (99.954%) and only 5,920 against.
Shifting of the Registered Office to Perungalathur, Chennai, approved to take effect from April 1, 2026.
The office relocation resolution passed with 99.99% support from participating shareholders.
A total of 103 shareholders participated in the remote e-voting process out of a base of 30,479 members.

💡 These resolutions are routine corporate governance and administrative matters that do not alter the company's financial outlook. Investors should remain focused on the company's core business performance and upcoming quarterly results.

MPS Ltd Q3 FY26: 9M Revenue INR 563.2 Cr, Unbound Medicine Acquisition for $16.5M

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 07 Feb 2026, 03:31 PM

MPS Limited reported a steady 9M FY26 performance with revenue reaching INR 563.2 crores, despite a slight dip in Q3 revenue to INR 182.5 crores. The Education Solutions segment showed robust growth of 38% in the first nine months, while Research Solutions remained the anchor with 61.1% revenue contribution. A major highlight is the USD 16.5 million acquisition of Unbound Medicine, a high-margin subscription business in the medical and nursing sector. Management remains confident in surpassing an EPS of INR 100 for FY26, supported by aggressive cost optimization and new synergies.

9M FY26 revenue reached INR 563.2 crores with Education Solutions segment growing over 38%
Q3 FY26 EBITDA margin stood at 31.6%, with the Education segment margins reaching 40.8%
Research Solutions contributed 61.1% of 9M revenue with 16.2% organic growth excluding AJE
Acquired 100% of Unbound Medicine for USD 16.5 million to secure high-margin recurring revenue
Management targets FY26 EPS to exceed INR 100, driven by cost optimization and platform synergies

💡 Investors should monitor the integration of Unbound Medicine as it shifts the business toward higher-margin recurring revenue. The management's confidence in achieving an EPS of INR 100+ suggests strong underlying profitability despite a transitional third quarter.

MPS Ltd Finalizes Funding for $16.5M Acquisition of Unbound Medicine via Debt and Accruals

🟢 POSITIVE ⭐ 8/10

M&A 📅 04 Feb 2026, 10:25 PM

MPS Limited has outlined a comprehensive funding structure for its USD 16.50 million acquisition of Unbound Medicine, Inc. The acquisition will be financed through a mix of internal accruals, inter-company loans totaling USD 4.94 million, and a new INR 420 million term loan from ICICI Bank. The company is infusing USD 9.81 million as equity into its US subsidiary, MPS North America LLC, to facilitate the transaction. This structured financing ensures the acquisition proceeds without diluting the parent company's 100% stake in its US operations.

Total acquisition consideration for Unbound Medicine, Inc. is USD 16.50 million.
Secured an INR 420 million term loan from ICICI Bank at a competitive interest rate of 7.85%.
Inter-company loans of USD 3.00 million and USD 1.94 million arranged to optimize group liquidity.
MPS Limited to infuse USD 9.81 million in equity into its wholly-owned subsidiary MPS North America LLC.
Funding involves a balanced mix of internal cash reserves and external borrowings.

💡 Investors should view this as a positive step toward inorganic growth, with a clear and structured financing plan in place. Monitor the integration of Unbound Medicine and its contribution to the company's consolidated revenue and margins in upcoming quarters.

MPS Limited Releases Q3 FY26 Earnings Conference Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Feb 2026, 08:32 PM

MPS Limited has officially released the audio recording of its earnings conference call held on February 2, 2026. The call focused on the company's unaudited financial results for the third quarter and the nine-month period ending December 31, 2025. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations to ensure transparency for all shareholders. Investors can access the recording on the company's website to hear management's detailed commentary on business performance and future outlook.

Earnings conference call conducted on February 2, 2026, at 5:00 PM IST.
Covers unaudited financial results for Q3 and the nine-month period ended December 31, 2025.
Audio recording link made available on the company's official website for public access.
Company confirmed that a written transcript of the call will be filed with stock exchanges in due course.

💡 Investors should listen to the audio recording or review the upcoming transcript to understand management's perspective on growth drivers and margin sustainability. No immediate trading action is required based solely on this procedural filing.

MPS Ltd Q3 PAT at ₹24.7 Cr; 9M Profit Jumps 25.8% YoY; Director Resigns

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 02 Feb 2026, 08:12 PM

MPS Limited reported a steady performance for the nine-month period ended December 2025, with standalone net profit rising 25.8% YoY to ₹81.68 crore. However, Q3 FY26 standalone revenue saw a marginal decline to ₹111.20 crore from ₹113.27 crore in the corresponding quarter last year. The company also announced the resignation of Ms. Yamini Tandon, a Non-Executive Director and Chairperson of the Stakeholders’ Relationship Committee, effective February 2, 2026. Additionally, the board approved the grant of 28,906 ESOPs to employees during the quarter.

Standalone Net Profit for 9M FY26 increased to ₹81.68 crore from ₹64.92 crore in 9M FY25.
Q3 FY26 Revenue from operations stood at ₹111.20 crore, slightly down from ₹113.27 crore YoY.
Basic Earnings Per Share (EPS) for the quarter ended December 31, 2025, was ₹14.44.
Ms. Yamini Tandon resigned from the Board and all committees due to personal reasons.
The company granted 28,906 stock options under the MPS Limited- Employee Stock Options Scheme 2023.

💡 Investors should look past the marginal Q3 revenue dip and focus on the strong 25.8% growth in nine-month profitability. Monitor the transition in the Stakeholders’ Relationship Committee following the director's resignation.

MPS Ltd Q3 FY26 Net Profit Rises 31.5% YoY to ₹28.52 Cr; Revenue Up 28% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 02 Feb 2026, 06:55 PM

MPS Limited reported a strong year-on-year performance for Q3 FY26, with standalone revenue growing 28.2% to ₹111.20 crore compared to ₹86.74 crore in the previous year. Net profit for the quarter stood at ₹28.52 crore, marking a 31.5% increase YoY, despite a marginal 1.8% dip in revenue on a sequential basis. The company also announced the resignation of Non-Executive Director Ms. Yamini Tandon and approved amendments to its Insider Trading Code. Additionally, the board noted the grant of 28,906 ESOPs to eligible employees during the quarter.

Standalone Revenue from operations grew 28.2% YoY to ₹11,120 lakhs in Q3 FY26.
Net Profit increased by 31.5% YoY to ₹2,852 lakhs from ₹2,168 lakhs in the same quarter last year.
Learning Solutions segment contributed ₹5,157 lakhs to revenue, while Content Solutions added ₹5,076 lakhs.
Basic EPS improved significantly to ₹16.66 from ₹12.67 in the corresponding quarter of the previous year.
Ms. Yamini Tandon resigned as Non-Executive Director effective February 2, 2026, due to personal reasons.

💡 Investors should take note of the robust year-on-year growth and healthy margins, which indicate strong operational execution. While the slight sequential revenue dip should be monitored, the overall financial trajectory remains positive for long-term holders.

MPS Limited Q3 FY26: PAT at ₹35.5 Cr; On Track for Record ₹100+ EPS in FY26

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 02 Feb 2026, 04:17 PM

MPS Limited reported a resilient performance for Q3 FY26 with revenues of ₹182.5 crore, despite a marginal 2.1% YoY decline. The core Research Solutions segment (excluding AJE) showed strong growth of 16.2% YoY, while Education Solutions grew by 11.3%. The company remains debt-free with a strong cash position of ₹143 crore and is confident of achieving its first-ever annual EPS of ₹100+ for FY26. Profitability in Q3 was impacted by a ₹7.02 crore exceptional provision related to the New Labour Code.

9M FY26 PAT grew by 23.9% YoY to ₹126.2 crore, with EBITDA margins improving to 29.9%.
Research Solutions (excl. AJE) revenue grew 16.2% YoY, maintaining a high EBITDA margin of 39.1%.
Education Solutions segment revenue increased 11.3% YoY to ₹44.3 crore with 40.8% EBITDA margins.
Company maintains a debt-free balance sheet with cash and equivalents of ₹143 crore as of Dec 2025.
Management expects to surpass ₹100 EPS for the first time in the company's history in FY26.

💡 Investors should focus on the strong 9M growth trajectory and the management's confidence in achieving record EPS. The core strength in Research and Education segments makes this a solid long-term play despite the temporary reset in Corporate Learning.

MPS Ltd Q3 FY26 Results: Net Profit Rises 15.5% YoY to ₹28.52 Cr; Revenue Up 23.6%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 02 Feb 2026, 04:01 PM

MPS Limited reported a strong performance for Q3 FY26, with revenue from operations growing 23.6% YoY to ₹111.20 crore. Net profit for the quarter increased by 15.5% YoY to ₹28.52 crore, supported by growth across its Content and Learning solutions segments. The company's EPS improved to ₹16.71 from ₹14.47 in the same quarter last year. Additionally, the board noted the resignation of Non-Executive Director Ms. Yamini Tandon and approved amendments to the insider trading code.

Revenue from operations grew 23.6% YoY to ₹11,120 lakhs in Q3 FY26.
Net profit increased 15.5% YoY to ₹2,852 lakhs, compared to ₹2,470 lakhs in Q3 FY25.
Content Solutions remains the largest segment, contributing ₹5,688 lakhs to quarterly revenue.
Basic EPS for the quarter rose to ₹16.71 from ₹14.47 in the previous year's corresponding quarter.
Nine-month (9M FY26) total income reached ₹32,880 lakhs with a net profit of ₹8,492 lakhs.

💡 Investors should view the consistent double-digit growth in revenue and profit as a sign of operational strength. The stock remains a positive hold given the steady margin profile and segment diversification.

MPS Limited Acquires 100% Stake in US-Based Healthcare Tech Firm Unbound Medicine

🟢 POSITIVE ⭐ 9/10

M&A 📅 31 Jan 2026, 12:02 AM

MPS Limited, through its US subsidiary, has entered into an agreement to acquire a 100% stake in Unbound Medicine, Inc., a Delaware-based healthcare technology company. Founded in 1999, Unbound Medicine provides digital medical reference and clinical decision-support solutions via a subscription-led institutional model. This acquisition marks MPS's strategic entry into the high-growth healthcare and medical information technology segment. The move aligns with the company's 'Vision 2027' strategy to focus on high-quality, recurring-revenue businesses with strong customer stickiness in the North American market.

Acquisition of 100% stake in Unbound Medicine, Inc. by wholly-owned subsidiary MPS North America LLC.
Unbound Medicine has a 26-year operational history serving leading medical schools and hospital systems in the US and Canada.
The target company operates a subscription-led business model, ensuring resilient and recurring revenue streams.
Strategic expansion into the healthcare vertical, diversifying MPS's portfolio beyond core digital publishing.
Integration with MPS Labs intended to accelerate AI-driven innovation in clinical tools and medical platforms.

💡 This acquisition is a significant positive as it adds a high-margin, recurring revenue stream in a specialized vertical. Investors should monitor upcoming financial disclosures for the deal valuation and the impact on consolidated EBITDA margins.

MPS Ltd to Acquire US-based Unbound Medicine for USD 16.5 Million

🟢 POSITIVE ⭐ 9/10

M&A 📅 30 Jan 2026, 11:56 PM

MPS Limited, through its US subsidiary, has entered into an agreement to acquire a 100% stake in Unbound Medicine, Inc. for USD 16.50 million in cash. Unbound Medicine is a healthcare learning technology company that reported USD 8.88 million in revenue for CY2024. The acquisition provides MPS entry into the high-growth medical information technology segment and adds over 480 institutional clients to its portfolio. This move is part of MPS's strategic vision to reach INR 1,500 crore in revenue by FY28.

Acquisition of 100% stake for a total cash consideration of USD 16.50 million
Target entity reported CY2024 revenue of USD 8.88 million with a high gross retention rate of ~97%
Adds 480+ institutional customers including medical schools and hospital systems across the US and Canada
Strategic entry into AI-enabled clinical decision support and healthcare learning platforms
Transaction expected to be completed on or before 10 February 2026

💡 Investors should view this as a positive strategic expansion into a high-margin, recurring revenue vertical that complements MPS's existing digital publishing business. Monitor the integration progress and the impact on consolidated margins in upcoming quarters.

View All MPSLTD Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

H1 FY26 consolidated revenue grew 6.22% YoY to INR 38,072 lakh. Research Solutions achieved 18.32% YoY organic growth in Q2 FY26, contributing 61.5% of total revenue. Education Solutions showed strong growth, while Corporate Learning contribution moderated.

Geographic Revenue Split

Not disclosed in available documents, though the company maintains global operations with leadership in Switzerland and Singapore.

Profitability Margins

PAT margin for H1 FY26 was 24.49%, up from 19.07% in H1 FY25. PBT margin expanded to 32.55% from 25.92% YoY, aided by higher operating leverage and exceptional income.

EBITDA Margin

EBITDA margin for H1 FY26 expanded by 271 bps YoY to 29.09%. Q2 FY26 EBITDA margin stood at 31.10%, a 99 bps YoY increase.

Capital Expenditure

The company has an enabling resolution for equity financing to deploy approximately INR 600 Cr for back-to-back acquisitions to reach its Vision 2027 revenue target of INR 1,500 Cr.

Credit Rating & Borrowing

The company maintains a debt-free balance sheet with zero debt as of 30 September 2025.

⚙️ Operational Drivers

Raw Materials

As a service-based business, primary costs are personnel-related; headcount stood at 3,071 as of H1 FY26, an 11.51% increase YoY.

Capacity Expansion

Current capacity is driven by a global workforce of 3,071 employees. Expansion is planned through a robust M&A pipeline of 25-35 active targets.

Raw Material Costs

Not applicable; however, operational efficiency gains and cost management initiatives improved EBITDA by 17.14% YoY to INR 11,076 lakh in H1 FY26.

Manufacturing Efficiency

Operational efficiency gains contributed to a 43.92% increase in Q2 FY26 performance.

📈 Strategic Growth

Expected Growth Rate

25-30%

Growth Strategy

The company aims to reach INR 1,500 Cr in revenue by FY27/28 through a combination of organic growth in Research Solutions (18.32% current organic growth) and an aggressive M&A strategy involving 5 back-to-back deals supported by an INR 600 Cr equity financing resolution. Strategic focus includes high-value opportunities like Experience Centers, with one project value recently scaling from $850,000 to $1.1 million.

Products & Services

Research Solutions, Education Solutions, Corporate Learning services, and Experience Centers.

Brand Portfolio

MPS Limited, MPS Interactive Systems Limited (MPSi).

New Products/Services

Expansion of Experience Centers (e.g., a $1.1 million project) and scaling strategic engagements in Research and Education segments.

Market Expansion

Targeting global markets through integrated leadership and specialist capabilities, with a focus on non-STAR clients.

Market Share & Ranking

Research Solutions maintains a dominant position in the portfolio, contributing 61.5% of total revenue.

🌍 External Factors

Industry Trends

The industry is seeing strong growth in Research and Education segments, while Corporate Learning has moderated. MPS is positioning itself as a cost-efficient global delivery partner with integrated specialist capabilities.

Competitive Landscape

The company competes in the global research, education, and corporate learning sectors, focusing on organic growth and aggressive M&A to gain market share.

Competitive Moat

Moat is built on a dominant position in Research Solutions (61.5% revenue share) and a consolidated, cost-efficient global delivery model that focuses on high-value, repeatable opportunities.

Macro Economic Sensitivity

Sensitivity to general regulatory and economic conditions affecting the industry.

Consumer Behavior

Shift toward high-value strategic engagements and experience-based learning solutions.

⚖️ Regulatory & Governance

Industry Regulations

Compliance with Ind AS 110 (Consolidated Financial Statements), Ind AS 108 (Operating Segments), and Section 133 of the Companies Act, 2013.

Taxation Policy Impact

Effective tax rate for H1 FY26 was approximately 24.7% based on PAT of INR 7,712 lakh and PBT of INR 10,251 lakh.

Legal Contingencies

No instances of significant fraud reported; unmodified review reports issued by statutory auditors Walker Chandiok & Co LLP.

⚠️ Risk Analysis

Key Uncertainties

Materialization of unknown risks or inaccurate underlying assumptions in the M&A strategy could impact the Vision 2027 revenue target of INR 1,500 Cr.